المؤلفون: Nicolas Girard, Eric Pichon, David Planchard, Didier Debieuvre, Radj Gervais, Gaëlle Chenuc, Pascale Dubray-Longeras, J. Otto, Eric Dansin, Hervé Lena, Anne Madroszyk, Maurice Pérol, Thomas Filleron, Xavier Quantin, Lise Bosquet, Gaëtane Simon, Coureche Kaderbhai, Sophie Cousin, Sandrine Hiret, Christelle Clément-Duchêne, Christos Chouaid, Roland Schott

المصدر: Targeted Oncology. 16:801-811

مصطلحات موضوعية: Male, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Population, Exon, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Humans, Pharmacology (medical), Epidermal growth factor receptor, education, Lung cancer, Protein Kinase Inhibitors, education.field_of_study, biology, Performance status, business.industry, Incidence (epidemiology), Combination chemotherapy, Exons, Immunotherapy, Middle Aged, medicine.disease, ErbB Receptors, Mutation, biology.protein, Female, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e82c91f8481d2a802c3a8c5a4cc4f86Test
https://doi.org/10.1007/s11523-021-00848-9Test

المؤلفون: Franck Morin, Judith Raimbourg, Didier Debieuvre, Denis Moro-Sibilot, Elisabeth Quoix, Hugues Morel, Elodie Amour, Olivier Molinier, José Hureaux, Etienne Giroux-Leprieur, Isabelle Rault, Alexis B. Cortot, Benjamin Huret, Josiane Otto, Aldo Renault, L. Moreau, Anne Madroszyk, Sandrine Charpentier, Marc G. Denis, Eric Pichon, Henri Berard, Jacques Cadranel

المساهمون: Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 (CANTHER), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), CHU Lille, Intergroupe Francophone de Cancérologie Thoracique [Paris] (IFCT), Intergroupe Francophone de Cancérologie thoracique, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], Centre Hospitalier Le Mans (CH Le Mans), CHU Strasbourg, Hopital d'instruction des armées Sainte-Anne [Toulon] (HIA), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), CHU Amiens-Picardie, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), CRLCC René Gauducheau, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Université Bretagne Loire (UBL), Hôpitaux Civils de Colmar, Centre Hospitalier Régional d'Orléans (CHRO), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Bristol-Myers Squibb, BMS, Pfizer, AstraZeneca, Merck, Novartis, Roche, Meso Scale Diagnostics, MSD, Boehringer Ingelheim, Takeda Pharmaceutical Company, TPC, and nonfinancial support from MSD, Takeda, and AbbVie outside the submitted work. E. Pichon reports nonfinancial support from Takeda, personal fees from Roche and AstraZeneca, and nonfinancial support from BMS outside the submitted work. B. Huret reports personal fees from Roche, AstraZeneca, BMS, and Boehringher Ingelheim outside the submitted work. M.G. Denis reports grants and personal fees from AstraZeneca and Takeda, grants from BluePrint Medicines, and personal fees from BMS, Boehringer Ingelheim, Roche Diagnostics, and Amgen outside the submitted work. J. Cadranel reports personal fees from BI, grants and personal fees from AstraZeneca, Pfizer, and Novartis, and personal fees from Roche, MSD, BMS, and Takeda outside the submitted work. No disclosures were reported by the other authors., A.B. Cortot reports grants from Boeringher-Ingelheim during the conduct of the study, as well as personal fees and nonfinancial support from AstraZeneca and Pfizer, grants, personal fees, and nonfinancial support from Roche and Novartis, personal fees and nonfinancial support from MSD, BMS, and Takeda, and grants from Merck, outside the submitted work. A. Madroszyk reports other support from Boehringer and MSD during the conduct of the study, as well as other support from Roche, Pfizer, AstraZeneca, BMS, and Prostrakan outside the submitted work. E. Giroux-Leprieur reports grants, personal fees, and nonfinancial support from AstraZeneca, Bristol Myers Squibb, and Roche, personal fees and nonfinancial support from Boehringer Ingelheim, MSD, and Takeda, and personal fees from Novartis outside the submitted work. O. Molinier reports personal fees from AstraZeneca, MSD, BMS, Amgen, Takeda, and Menarini outside the submitted work. E. Quoix reports grants from Boehringer Ingelheim and Ligue Nationale contre le Cancer during the conduct of the study, as well as personal fees and other from BMS and Chugai, other from Roche and Takeda, and personal fees from Novartis outside the submitted work. H. Bérard reports other from MSD, Roche, and Novartis outside the submitted work. D. Moro-Sibilot reports grants, personal fees, and nonfinancial support from Boehringer Ingelheim, Roche, BMS, Pfizer, AstraZeneca, and Merck, as well as personal fees, Medical writing assistance was provided by Dr Sarah Hopwood (Scinopsis, France), funded by IFCT. We thank the participating patients and their families as well as the study teams involved in the trial, the clinical research assistants, study coordinators, and IFCT operations staff. We thank the staff of the department of Biochemistry, CHU de Nantes. We also thank all the participating investigators: Dr Anne Madroszyk (institut Paoli Calmette, Marseille), Dr Etienne Giroux-Leprieur (hôpital Ambroise Paré, Boulogne), Dr Olivier Molinier (CHG, Le Mans), Pr Elisabeth Quoix (NHC, Strasbourg), Pr Jacques Cadranel (hôpital Tenon, Paris), Dr Henri Bérard (HIA Sainte-Anne, Toulon), Dr Josiane Otto (centre Antoine Lacassagne, Nice), Dr Isabelle Rault (CH, Saint Quentin), Pr Denis Moro-Sibilot (CHU, Grenoble), Pr Alexis B. Cortot (hôpital Calmette, Lille), Dr Judith Raimbourg (Institut de Cancérologie de l’Ouest, Nantes), Dr José Hureaux (CHU Angers), Lionel Moreau (CH Colmar), Dr Didier Debieuvre (GHRMSA, Mulhouse), Dr Hugues Morel (CHR, Orléans), Dr Valérie Gounant (hôpital Bichat, Paris), Dr Ludovic Doucet (hôpital Saint-Louis, Paris), Dr Aldo Renault (CHG, Pau), Dr Eric Pichon (CHU, Tours), Dr Benjamin Huret (hôpital privé, Villeneuve d’Asq), Dr Nadine Dohollou (Polyclinique Bordeaux Nord), Dr Clarisse Audigier-Valette (CHI, Toulon), Dr Chantal Decroisette (CH, Annecy), Dr Mathilde Cabart (Institut Bergonié, Bordeaux), Dr Patrick Merle (CHU, Clermont-Ferrand), Dr Catherine Becht (clinique du Parc, Castelnau le Lez), and Dr Luc Odier (CH, Villefranche sur Saône)., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)

المصدر: Clinical Cancer Research
Clinical Cancer Research, American Association for Cancer Research, 2021, 27 (15), pp.4168-4176. ⟨10.1158/1078-0432.CCR-20-4604⟩
Clinical Cancer Research, 2021, 27 (15), pp.4168-4176. ⟨10.1158/1078-0432.CCR-20-4604⟩

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, medicine.drug_class, Afatinib, [SDV.CAN]Life Sciences [q-bio]/Cancer, EGFR Gene Mutation, Tyrosine-kinase inhibitor, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Clinical endpoint, Epidermal growth factor receptor, Adverse effect, Lung cancer, 030304 developmental biology, 0303 health sciences, Cetuximab, biology, business.industry, medicine.disease, 3. Good health, 030220 oncology & carcinogenesis, biology.protein, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76cc6aa17b0f36d03ffa1da497689d14Test
https://hal.archives-ouvertes.fr/hal-03401841Test

المؤلفون: Nathalie Baize, Christos Chouaid, Lionel Falchero, Patrick Saulnier, Jean-Bernard Auliac, Roland Schott, Groupe Français de Pneumo-Cancérologie – investigators, Laurent Greillier, R. Lamy, Hervé Le Caer, Jacques Letreut, Jacky Crequit, Gwenaelle Le Garff, A. Madroszyk, Radj Gervais, Margaux Geier, Isabelle Monnet, Patrick-Aldo Renault, Alain Vergnenegre, Henri Berard, Eric Dansin, H. Janicot, Hervé Lena

المصدر: The Lancet Oncology. 21:1224-1233

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, medicine.medical_specialty, Adolescent, Drug-Related Side Effects and Adverse Reactions, medicine.medical_treatment, Population, Disease-Free Survival, Carboplatin, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Lung cancer, education, Etoposide, Aged, Chemotherapy, education.field_of_study, business.industry, Combination chemotherapy, Middle Aged, medicine.disease, Small Cell Lung Carcinoma, 030104 developmental biology, Oncology, chemistry, 030220 oncology & carcinogenesis, Female, Topotecan, France, Neoplasm Recurrence, Local, business, Febrile neutropenia, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84b2892288de0f63aa230ce4a3c45fe6Test
https://doi.org/10.1016/s1470-2045Test(20)30461-7

المؤلفون: Renaud Sabatier, Magali Provansal, Patrice Viens, Patrick Sfumato, Séverine Garnier, Jihane Pakradouni, Flora Poizat, Emilien Billon, Pascal Finetti, Arnaud Guille, Jean-Marc Extra, Nadine Carbuccia, Emilie Mamessier, Olivier Turrini, Anthony Gonçalves, Cornel Popovici, Fabrice Andre, Eric Lambaudie, Cecile Vicier, Lénaïg Mescam, Audrey Monneur, Daniel Birnbaum, Martin Khran, Gwenaelle Gravis, Christophe Pécheux, Emmanuelle Charafe-Jauffret, Jeanne Thomassin-Piana, François Bertucci, Christian Chabannon, Max Chaffanet, Anne Madroszyk, Serge Brunelle, José Adélaïde, Marine Gilabert

المساهمون: Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Hôpital de la Timone [CHU - APHM] (TIMONE), Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Gustave Roussy (IGR), Biomarqueurs prédictifs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse (U981), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), mamessier, emilie, Département de génétique médicale [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM)

المصدر: Genome Medicine
Genome Medicine, 2021, 13 (1), pp.87. ⟨10.1186/s13073-021-00897-9⟩
Genome Medicine, Vol 13, Iss 1, Pp 1-20 (2021)

مصطلحات موضوعية: Oncology, Male, Biopsy, QH426-470, medicine.disease_cause, Neoplasms, PERMED-01 trial, Clinical endpoint, Sequencing, Prospective Studies, Genetics (clinical), Aged, 80 and over, Comparative Genomic Hybridization, medicine.diagnostic_test, biology, Precision medicine, Disease Management, High-Throughput Nucleotide Sequencing, Genomics, Middle Aged, Prognosis, Combined Modality Therapy, Treatment Outcome, Molecular Diagnostic Techniques, Molecular Medicine, Medicine, WES, Female, KRAS, Disease Susceptibility, [SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy, Advanced cancers, Adult, medicine.medical_specialty, [SDV.CAN]Life Sciences [q-bio]/Cancer, Young Adult, aCGH, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, Genetics, Biomarkers, Tumor, PTEN, Humans, Molecular Biology, t-NGS, Aged, Neoplasm Staging, business.industry, Research, Cancer, Genetic Variation, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, medicine.disease, Human genetics, Clinical trial, Mutation, biology.protein, Neoplasm Grading, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6fbe58a797962887c649f4db544c93eTest
https://hal.science/hal-03583277Test

المؤلفون: Jacques Le Treut, Catherine Dubos-Arvis, O. Bylicki, Alain Vergnenegre, Jacky Crequit, Marie Marcq, Gwenaelle Le Garff, Nicolas Paleiron, Victor Basse, Isabelle Monnet, Pascal Thomas, Gislaine Fraboulet, Bénédicte Comet, Anne Madroszyk, Jean-Bernard Auliac

المصدر: Cancer Management and Research. 11:10821-10826

مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Lung, business.industry, Disease, medicine.disease, Systemic therapy, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Internal medicine, medicine, Squamous non-small cell lung cancer, Observational study, Ineligibility, business, Prospective cohort study, Lung cancer

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::b4dc334dd9dfaa6871f5f7217af11d1bTest
https://doi.org/10.2147/cmar.s219984Test

المؤلفون: Anne Marie Chiappa, Isabelle Monnet, Radj Gervais, Christos Chouaid, Alain Vergnenegre, S. Vieillot, Jean Bernard Auliac, Roland Schott, Gilles Robinet, Laurent Greillier, Lionel Falchero, Anne Madroszyk, R. Lamy, Pascal Thomas, Charles Ricordel, Samir Abdiche, Stephane Chouabe, Henri Berard, Chantal Decroisette

المساهمون: CHI Créteil, CHU Limoges, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hopital d'instruction des armées Sainte-Anne [Toulon] (HIA), Groupe Hospitalier Bretagne Sud (GHBS), Centre Paul Strauss, CRLCC Paul Strauss, CHU Pontchaillou [Rennes], Centre Hospitalier de Charleville-Mezières, Hôpital de GAP, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Hospitalier Libourne, CH de Quimper, Hôpital Nord [CHU - APHM]

المصدر: Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, SAGE Journals, 2021, 13, pp.175883592110069. ⟨10.1177/17588359211006983⟩

مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Bevacizumab, medicine.medical_treatment, non-small–cell lung cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer, bevacizumab, Asymptomatic, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, Lung cancer, pemetrexed, radiotherapy, RC254-282, cerebral metastasis, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Carboplatin, Radiation therapy, 030104 developmental biology, Pemetrexed, chemistry, 030220 oncology & carcinogenesis, medicine.symptom, business, management, medicine.drug, Brain metastasis

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44ff0277eb53f2530508c3b2d27143d2Test
https://doaj.org/article/a1b5190caa744a0094132ccad24a69d7Test

المؤلفون: Philippe Rochigneux, Alejandro J. Garcia, Brice Chanez, Anne Madroszyk, Daniel Olive, Edward B. Garon

المساهمون: Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU)

المصدر: Frontiers in Immunology
Frontiers in Immunology, 2020, 11, ⟨10.3389/fimmu.2020.01036⟩
Frontiers in Immunology, Frontiers, 2020, 11, ⟨10.3389/fimmu.2020.01036⟩
Frontiers in Immunology, Vol 11 (2020)

مصطلحات موضوعية: lcsh:Immunologic diseases. Allergy, 0301 basic medicine, Lung Neoplasms, immune monitoring, medicine.medical_treatment, Immunology, Antineoplastic Agents, Review, chemotherapy, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Immune system, Monitoring, Immunologic, medicine, Biomarkers, Tumor, Immunology and Allergy, Humans, Mass cytometry, Molecular Targeted Therapy, Lung cancer, Immune Checkpoint Inhibitors, ComputingMilieux_MISCELLANEOUS, business.industry, Immunotherapy, medicine.disease, Immune checkpoint, 3. Good health, Biomarker (cell), lung cancer, 030104 developmental biology, Treatment Outcome, DNA methylation, Cancer research, [SDV.IMM]Life Sciences [q-bio]/Immunology, immunotherapy, lcsh:RC581-607, business, immune biomarker, 030215 immunology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::802e03c21f189291905d8281d206e361Test
https://hal-amu.archives-ouvertes.fr/hal-03152719Test

المؤلفون: Philippe Masson, Denis Moro-Sibilot, Isabelle Monnet, Anne-Claire Toffart, Bertrand Mennecier, Didier Debieuvre, E. Amour, Eric Pichon, Fabrice Barlesi, Olivier Molinier, Franck Morin, Patrick Aldo Renault, Anne Madroszyk-Flandin, Séverine Fraboulet, Isabelle Rouquette, Alexis B. Cortot, Pierre Jean Souquet, Virginie Westeel, Sandrine Hiret, Clarisse Audigier-Valette, Julien Mazieres, Benjamin Besse, Gérard Zalcman

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research. 26(13)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, law.invention, 03 medical and health sciences, 0302 clinical medicine, Gefitinib, Randomized controlled trial, Estrogen Receptor Modulators, law, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Biomarkers, Tumor, Humans, Lung cancer, neoplasms, Protein Kinase Inhibitors, Aged, Neoplasm Staging, Aged, 80 and over, Fulvestrant, business.industry, Middle Aged, Antiestrogen, medicine.disease, Prognosis, respiratory tract diseases, Clinical trial, ErbB Receptors, 030104 developmental biology, Treatment Outcome, 030220 oncology & carcinogenesis, Mutation, Female, Erlotinib, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ecbc189802ce70dfbd0a491c5fd17ccTest
https://pubmed.ncbi.nlm.nih.gov/32144133Test

المؤلفون: F. El Hajbi, Aurélie Ferru, Jérôme Desramé, Jeannick Madelaine, Franck Morin, D. Smith, C. Louvet, T. Egenod, J. Otto, Thomas Walter, Hervé Lena, J. Mazieres, Christelle Clément-Duchêne, Nicolas Girard, Virginie Westeel, Alexandra Langlais, C. Lepage, L. Gérinière, Anne Madroszyk, Pierre Michel

المصدر: Annals of Oncology. 32:S1318

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Poorly differentiated, Ipilimumab, Hematology, Neuroendocrine tumors, medicine.disease, Refractory, Internal medicine, medicine, Nivolumab, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::933b860df7c96520ee8c6727040dab93Test
https://doi.org/10.1016/j.annonc.2021.08.2119Test

المؤلفون: Frederico Cappuzzo, Didier Debieuvre, Benjamin Besse, Domenico Galetta, E. Quoix, M. Phan, Fabrice Denis, G. Romano, M.R. Garcia Campelo, M. Cobo Dols, Alona Zer, Santiago Viteri, Rafal Dziadziuszko, Wolfgang Schuette, W. Hilgers, Editta Baldini, Anne Madroszyk, Enriqueta Felip, D. Costantini, Giuseppe Giaccone

المصدر: Annals of Oncology. 32:S1325

مصطلحات موضوعية: 2019-20 coronavirus outbreak, Text mining, Oncology, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immune checkpoint inhibitors, Cancer research, medicine, non-small cell lung cancer (NSCLC), Hematology, medicine.disease, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::ade845d8527ad50c48376f4546124cf3Test
https://doi.org/10.1016/j.annonc.2021.08.2126Test